Emergent BioSolutions (EBS) Capital Expenditures Growth (3y) (2013 - 2026)
Emergent BioSolutions (EBS) Capital Expenditures Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -4.39% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -11.01% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -0.22% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 34.19% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -8.00% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 4.68% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -7.72% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Emergent BioSolutions | 251.81 Mn | 110.91 Mn | 137.20 Mn | -44.82% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -44.82% |
| Mar 31, 2026 | -32.49% |
| Dec 31, 2025 | 86.58% |
| Sep 30, 2025 | -29.43% |
| Jun 30, 2025 | -55.13% |
| Mar 31, 2025 | -51.83% |
| Dec 31, 2024 | -56.03% |
| Sep 30, 2024 | 29.72% |
| Jun 30, 2024 | 157.76% |
| Mar 31, 2024 | -53.35% |
| Dec 31, 2023 | 85.38% |
| Sep 30, 2023 | 28.15% |
| Jun 30, 2023 | -17.37% |
| Mar 31, 2023 | -31.44% |
| Dec 31, 2022 | -29.08% |
| Sep 30, 2022 | 22.17% |
| Jun 30, 2022 | 4.17% |
| Mar 31, 2022 | 65.53% |
| Dec 31, 2021 | 36.56% |
| Sep 30, 2021 | -47.58% |